Sacubitril sodium
Based on 3 publication(s) in Google Scholar
Sacubitril sodium is a potent and orally active NEP (neprilysin) inhibitor, with an IC50 of 5 nM. Sacubitril sodium enhances the tone of the natriuretic peptide (NP) system and exerts significant antihypertensive effects. Sacubitril sodium is a component of the heart failure medicine LCZ696. Sacubitril sodium can be used for the research of heart failure, hypertension and COVID-19.
For research use only. We do not sell to patients.
- Purity: 99.95%
- CAS No.: 149690-05-1
- Formula: C24H28NNaO5
- Molecular Weight:433.47
-
Storage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Anti-Infection Compound Library
HY-L002
-
Metabolism/Protease Compound Library
HY-L012
-
FDA-Approved Drug Library
HY-L022
-
Drug Repurposing Compound Library
HY-L035
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Rare Diseases Drug Library
HY-L102
-
EMA-Approved Drug Library
HY-L116
-
Off-patent Drug Library
HY-L141
-
Antihypertensive Compound Library
HY-L145
-
Metabolic Enzyme Compound Library
HY-L146
-
Protease Inhibitor Library
HY-L147
-
Membrane Protein-targeted Compound Library
HY-L149
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) Sacubitril sodium
More
Customer Validation & Images
-
ELISA
Biological Activity
Sacubitril sodium increases neprylisin-degraded peptides, such as natriuretic peptides (NPs), peptide natriuretic atrial (ANP) and peptide natriuretic brain (BNP)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Sacubitril sodium (30 and 100 mg/kg, PO) produces a dose-dependent antihypertensive effect in Dahl-SS rats[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 149690-05-1
-
Appearance Solid
-
Molecular Weight 433.47
-
Formula C24H28NNaO5
-
Color White to off-white
-
SMILES
O=C(CCC(O[Na])=O)N[C@H](CC1=CC=C(C2=CC=CC=C2)C=C1)C[C@@H](C)C(OCC)=O
-
Synonyms
AHU-377 sodium
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Cardiovasc Diabetol
Sacubitril/Valsartan partially alleviates myocardial infarction injury by activating the FGF21 signaling pathway via PPARs. [Abstract]2025 Feb 22;24(1):89. PMID: 39987117 -
Theranostics
Activating AhR alleviates cognitive deficits of Alzheimer's disease model mice by upregulating endogenous Aβ catabolic enzyme Neprilysin. [Abstract]2021 Aug 11;11(18):8797-8812. PMID: 34522212
Sacubitril sodium purchased from MedChemExpress. Usage Cited in: Theranostics. 2021 Aug 11;11(18):8797-8812. [Abstract]
N2a-APP cells were treated with Diosmin (Dio; 80 μM), FICZ (250 nM), L-KN (3 μM) or Indole-3-acetamide (I3C; 10 μM) with or without SR1 (2 μM) or Sacubitril (Sac; 1 μM) for 24 h, the supernatant was collected and the Aβ42 levels were determined by ELISA.
-
Mol Biol Rep
Cardiac drug potential: exploring individual and combined cardiac drugs to promote differentiation of adipose-derived stem cells into cardiomyocytes. [Abstract]2026 Feb 26;53(1):434. PMID: 41746444
Solvent & Solubility
DMSO : 50 mg/mL (115.35 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[2]. Vitiello A, et al. Sacubitril, valsartan and SARS-CoV-2. BMJ Evid Based Med. 2020 Jul 27:bmjebm-2020-111497. [Content Brief]
[3]. Chrysant SG. Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan. J Am Soc Hypertens. 2017 Jul;11(7):461-468. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3070 mL | 11.5348 mL | 23.0696 mL | 57.6741 mL |
| 5 mM | 0.4614 mL | 2.3070 mL | 4.6139 mL | 11.5348 mL | |
| 10 mM | 0.2307 mL | 1.1535 mL | 2.3070 mL | 5.7674 mL | |
| 15 mM | 0.1538 mL | 0.7690 mL | 1.5380 mL | 3.8449 mL | |
| 20 mM | 0.1153 mL | 0.5767 mL | 1.1535 mL | 2.8837 mL | |
| 25 mM | 0.0923 mL | 0.4614 mL | 0.9228 mL | 2.3070 mL | |
| 30 mM | 0.0769 mL | 0.3845 mL | 0.7690 mL | 1.9225 mL | |
| 40 mM | 0.0577 mL | 0.2884 mL | 0.5767 mL | 1.4419 mL | |
| 50 mM | 0.0461 mL | 0.2307 mL | 0.4614 mL | 1.1535 mL | |
| 60 mM | 0.0384 mL | 0.1922 mL | 0.3845 mL | 0.9612 mL | |
| 80 mM | 0.0288 mL | 0.1442 mL | 0.2884 mL | 0.7209 mL | |
| 100 mM | 0.0231 mL | 0.1153 mL | 0.2307 mL | 0.5767 mL |
Sacubitril sodium Related Classifications
HY-15407B Related Classifications
Powered by Bioz